7,129 Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas

Smith Chas P & Associates PA Cpas decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 238,267 shares of the company’s stock after selling 7,129 shares during the period. Johnson & Johnson comprises approximately 3.0% of Smith Chas P & Associates PA Cpas’ investment portfolio, making the stock its 8th biggest holding. Smith Chas P & Associates PA Cpas’ holdings in Johnson & Johnson were worth $60,891,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in JNJ. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $28,000. Matrix Trust Co raised its stake in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $43,000. Polaris Financial Partners acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $56,000. Finally, Bullseye Investment Management LLC bought a new position in Johnson & Johnson during the second quarter worth $63,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.3%

Shares of Johnson & Johnson stock opened at $264.13 on Friday. The firm has a 50-day moving average of $265.64 and a 200-day moving average of $250.21. The stock has a market cap of $635.85 billion, a PE ratio of 40.02, a PEG ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 64,515 shares of company stock valued at $17,271,766. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Scotiabank reiterated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Finally, HSBC increased their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.